Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials

BACKGROUND: To compare the efficacy and toxicity of anti-programmed cell death receptor 1 (PD-1) and anti-programmed cell death ligand 1 (PD-L1) versus docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: Phase III randomised clinical tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramos-Esquivel, Allan, van der Laat, Alicia, Rojas-Vigott, Raquel, Juárez, Melissa, Corrales-Rodríguez, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5699523/
https://www.ncbi.nlm.nih.gov/pubmed/29181191
http://dx.doi.org/10.1136/esmoopen-2017-000236

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5699523/
https://www.ncbi.nlm.nih.gov/pubmed/29181191
http://dx.doi.org/10.1136/esmoopen-2017-000236

Ejemplares similares